VRDN - NASDAQ

Viridian Therapeutics, Inc.

VRDN·NASDAQ

$16.92

+6.6%

HealthcareBiotechnology

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.52B

EPS-3.3200

P/E Ratio-5.10

Earnings Date08/05/2026

899.42M

Assets

21%

3Y+107.0%

5Y+585.0%

10Y+21018.0%

177.25M

Total Liabilities

150%

3Y+343.0%

5Y+1480.0%

10Y+3766.0%

722.17M

Total Equity

3Y+83.0%

5Y+502.0%

10Y-221624.0%

Viridian Therapeutics, Inc. Funding & Solvency Profile

VRDN · NASDAQ

Current Assets

Cash & Cash Equivalents212.38M

Net Receivables0.00

Inventory0.00

Other Current Assets19.58M

Total Current Assets894 M

Non-Current Assets

Property, Plant & Equipment3.65M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.54M

Total Non-Current Assets5 M

Total Assets

899.42M

Financial Health Analysis

Current Ratio

12.65x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.25x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

824 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Viridian Therapeutics, Inc. Balance Sheet

VRDN • NASDAQ

Viridian Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	212.4M	99.6M	102.8M	155.6M	42.3M	45.9M	24.8M	32.6M	47.4M	3.3M	10.8M	5.1M	209.3K	112.5K
Short-Term Investments	662.3M	618M	374.5M	269M	154.7M	81.7M	2M	29.9M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	874.7M	717.6M	477.4M	424.6M	197M	127.6M	26.8M	62.5M	47.4M	3.3M	10.8M	5.1M	209.3K	112.5K
Net Receivables	0.0	0.0	102K	102K	451K	0.0	108K	24K	1.5M	524K	394K	1.1M	994K	1.2M
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	108K	24K	1.5M	524K	394K	1.1M	994K	1.2M
Other Receivables	0.0	0.0	102K	102K	451K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	-6.6M	0.0	0.0	0.0	0.0	0.0	64K	187K	179K	356.6K	169.5K
Prepaids	0.0	0.0	0.0	0.0	2.7M	2M	2.9M	2.4M	1.9M	160K	321K	399K	445K	129.6K
Other Current Assets	19.6M	20.9M	9M	6.5M	0.0	0.0	-108K	2.9M	3M	170K	321K	0.0	50K	56.2K
Total Current Assets	894.2M	738.5M	486.5M	424.6M	200.2M	129.6M	29.7M	65.4M	51.9M	4.3M	11.7M	6.8M	2.1M	1.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	3.6M	3.4M	3.3M	2.9M	2.1M	787K	523K	727K	563K	625K	1.2M	1.2M	928K	1.1M
Other Non-Current Assets	1.5M	501K	604K	7.6M	1.5M	857K	0.0	50K	50K	258K	15K	90K	690.1K	45.6K
Total Non-Current Assets	5.2M	3.9M	3.9M	10.5M	3.5M	1.6M	523K	777K	613K	883K	1.2M	1.3M	1.6M	1.1M
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-883K	0.0	0.0	0.0	0.0
Total Assets	899.4M	742.4M	490.4M	435.1M	203.7M	131.3M	30.3M	66.1M	52.5M	4.3M	12.9M	8.1M	3.7M	2.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	8.7M	2.1M	2.2M	14.2M	2.3M	670K	1.1M	571K	906K	159K	242K	255K	419K	330.4K
Accounts Payable	8.7M	2.1M	2.2M	14.2M	2.3M	670K	1.1M	571K	906K	159K	242K	255K	100K	26.7K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-100K	303.7K
Accrued Expenses	0.0	34.2M	10.5M	13.3M	6.7M	2M	4.4M	3.6M	2.6M	3.3M	826K	257K	76.4K	484.5K
Short Term Debt	753K	0.0	0.0	0.0	0.0	0.0	4M	2.3M	0.0	0.0	1.1M	80K	697.1K	22.6M
Capital Lease Obligations (Current)	0.0	513K	843K	613K	520K	455K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	76.4K	0.0
Deferred Revenue	0.0	288K	288K	288K	289K	301K	0.0	3.8M	0.0	3.4M	1M	0.0	76.4K	788.2K
Other Current Liabilities	61.3M	10.7M	12.8M	4.9M	3.8M	7.3M	674K	239K	353K	1.2M	295K	1.4M	194.3K	200K
Total Current Liabilities	70.7M	47.9M	26.6M	33.3M	13.6M	10.7M	10.2M	6.7M	3.9M	4.6M	2.5M	2M	1.4M	23.6M
NON-CURRENT LIABILITIES
Long Term Debt	49.9M	20.6M	20.2M	4.6M	0.0	0.0	4.3M	8M	9.9M	2.8M	0.0	0.0	0.0	42K
Deferred Revenue (Non-Current)	0.0	284K	573K	861K	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	56.6M	2M	989K	1.2M	1.2M	544K	0.0	66K	152K	0.0	24K	109K	259.3K	578.8K
Total Non-Current Liabilities	106.6M	22.9M	21.8M	6.7M	2.4M	544K	4.3M	8.1M	10.1M	2.8M	24K	109K	259.3K	620.8K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.8M	0.0	0.0	0.0	0.0
Capital Lease Obligations	0.0	513K	843K	613K	520K	455K	0.0	0.0	0.0	0.0	0.0	80K	0.0	0.0
Total Liabilities	177.3M	70.8M	48.4M	40M	16M	11.2M	14.5M	14.8M	14M	4.6M	2.5M	2.1M	1.6M	24.2M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5.1M	0.0	0.0	0.0	0.0
Preferred Stock	132.1M	188.9M	206.5M	142.1M	133.8M	180.8M	0.0	0.0	52.5M	77M	60.9M	36.1M	0.0	0.0
Common Stock	1M	810K	540K	414K	239K	42K	23K	308K	226K	7K	106K	38K	27.9K	0.0
Additional Paid-In Capital	1.9B	1.5B	960.5M	741.1M	412.1M	218.1M	183.9M	177.3M	131.9M	5.1M	28.3M	12.6M	27.9M	0.0
Retained Earnings	-1.3B	-995.9M	-725.9M	-488.2M	-358.3M	-278.9M	-168.2M	-126.3M	-93.6M	-30.6M	-18M	-6.6M	-25.9M	-21.4M
Accumulated Other Comprehensive Income/Loss	447K	-10K	338K	-390K	-157K	-8K	0.0	-3K	-2.8M	0.0	-739K	-555K	-411.1K	-262.7K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-51.8M	0.0	0.0	411.1K	262.7K
Total Stockholders' Equity	722.2M	671.6M	442M	395.1M	187.7M	120M	15.8M	51.3M	38.5M	-326K	10.4M	6M	2M	-21.4M
Total Equity	722.2M	671.6M	442M	395.1M	187.7M	120M	15.8M	51.3M	38.5M	-326K	10.4M	6M	2M	-21.4M
SUMMARY
Total Liabilities & Equity	899.4M	742.4M	490.4M	435.1M	203.7M	131.3M	30.3M	66.1M	52.5M	4.3M	12.9M	8.1M	3.7M	2.8M
Total Investments	662.3M	618M	374.5M	269M	154.7M	81.7M	2M	29.9M	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	50.7M	21.1M	21M	5.3M	520K	455K	8.3M	10.3M	9.9M	1M	1.1M	80K	697.1K	22.6M
Net Debt	-161.7M	-78.5M	-81.8M	-150.3M	-41.8M	-45.4M	-16.5M	-22.3M	-37.5M	-2.3M	-9.7M	-5M	487.7K	22.5M
Shares Outstanding	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045	81,180,045

SEC Filings

VRDN - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 28, 2026	May 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 26, 2026	May 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 17, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 30, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing

Showing 1 to 10 of 260 filings

Related Guides

Blog Categories

Continue your VRDN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.